Eli Lilly’s third quarter earnings miss and forecast cut lead to sharp stock drop
Eli Lilly is dialing back its 2024 forecast after underwhelming Wall Street with third-quarter earnings and sales from two ...
Nasdaq edges back from its record as chip companies and Eli Lilly slump
U.S. stock indexes edged lower after drops for Eli Lilly and chip companies overshadowed a jump for Google's parent company ...
What You May Have Missed From Eli Lilly's Q3 2024 Earnings Disappointment
LLY’s slashed revenue and earnings guidance for 2024 were a surprise, especially given substantial raises to its outlook ...
Eli Lilly's Zepbound and Mounjaro are no longer in shortage. Here's where their sales still disappointed
During an earnings call Wednesday, Eli Lilly instead blamed it on drug wholesalers cutting inventory of Zepbound and Mounjaro ...
Stocks hit pause after Nasdaq milestone; Eli Lilly earnings underwhelm Wall St.
The S&P 500 slipped 0.3 percent after drifting between small gains and losses several times, though it's still near its ...
Eli Lilly: The Stock Might Have Peaked
Eli Lilly and Company disappointed with missed earnings, lower guidance. Click here for my review of LLY Q3 earnings and a ...
Biotech backed by Eli Lilly, Merck raises $175 million
Aktis, in a statement announcing the round, said all existing institutional investors also participated, as did strategic ...
Eli Lilly’s Ebglyss: A Promising Alternative for Dupixent-Resistant Atopic Dermatitis Patients
Leerink Partners analyst David Risinger has maintained their bullish stance on LLY stock, giving a Buy rating today. David Risinger’s ...